General remarks on the substances considered

IARC Monographs on the Evaluation of Carcinogenic Risks to Humans

Volumn 76, Issue , 2000, Pages 35-42

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMSACRINE; ANTIVIRUS AGENT; DIDANOSINE; ETOPOSIDE; GYRASE INHIBITOR; HYDROXYUREA; MITOXANTRONE; PHENOLPHTHALEIN; TENIPOSIDE; VITAMIN K GROUP; ZALCITABINE; ZIDOVUDINE;

CANCER COMBINATION CHEMOTHERAPY; CARCINOGENICITY; CHEMICAL CARCINOGENESIS; CHROMOSOME TRANSLOCATION; DNA CLEAVAGE; EPSTEIN BARR VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; KAPOSI SARCOMA; MEDICAL LITERATURE; MYELOID LEUKEMIA; NONHODGKIN LYMPHOMA; PRENATAL EXPOSURE; PRIORITY JOURNAL; REVIEW; SECOND CANCER;

EID: 0033941349     PISSN: 02509555     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (34)

1. Baguley, B.C. & Ferguson, L.R. (1998) Mutagenic properties of topoisomerase-targeted drugs. Biochim. biophys. Acta, 1400, 213-222
2. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. & Sultan, C. (1985) Proposed revised criteria for the classification of acute myeloid leukemia, a report of the French-American-British cooperative group. Ann. intern. Med., 103, 620-629
3. Berger, J.M. (1998) Structure of DNA topoisomerases. Biochim. biophys. Acta, 1400, 3-18
4. Burden, D.A. & Osheroff, N. (1998) Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim. biophys. Acta, 1400, 139-154
5. Centers for Disease Control and Prevention (1998) Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Morb. Mortal. wkly Rep., 47 (RR-5), 42-82
6. Cheson, B.D., Cassileth, P.A., Head, D.R., Schiffer, C.A., Bennett, J.M., Bloomfield, C.D., Brunning, R., Gale, R.P., Grever, M.R., Keating, M. J., Sawitzky, A., Stass, S., Weinstein, H. & Woods, W.G. (1990) Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J. clin. Oncol., 8, 813-819
7. Corbett, A.H. & Osheroff, N. (1993) When good enzymes go bad: Conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem. Res. Toxicol., 6, 585-597
8. Corral, J., Lavenir, I., Impey, H., Warren, A.J., Forster, A., Larson, T.A., Bell, S., McKenzie, A.N., King, G. & Rabbitts, T.H. (1996) An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes. Cell, 85, 853-861
9. Englund, J.A., Baker, C.J., Raskino, C., McKinney, R.E., Petrie, B., Fowler, M.G., Pearson, D., Gershon, A., McSherry, G.D., Abrams, E.J., Schliozberg, J. & Sullivan, J.L. (1997) Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. New Engl. J. Med., 24, 1704-1712
10. Felix, C. & Lange, B. (1999) Leukemia in infants. Oncologist, 4, 225-240
11. Felix, C.A., Hosler, M.R., Provisor, D., Salhany, K., Sexsmith, E.A., Slater, D.J., Cheung, N.K., Winick, N.J., Strauss, E.A., Heyn, R., Lange, B.J. & Malkin, D. (1996) The p53 gene in pediatric therapy-related leukemia and myelodysplasia. Blood, 87, 4376-4381
12. Felix, C.A., Walker, A.H., Lange, B.J., Williams, T.M., Winick, N.J., Cheung, N.K., Lovett, B.D., Nowell, P.C., Blair, I.A. & Rebbeck, T.R. (1998) Association of CYP3A4 genotype with treatment-related leukemia. Proc. natl Acad. Sci. USA, 95, 13176-13181
13. Ford, A.M., Ridge, S.A., Cabrera, M.E., Mahmoud, H., Steel, C.M., Chan, L.C. & Greaves, M. (1993) In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature, 363, 358-360
14. Gale, K., Ford, A., Repp, R., Borkhardt, A., Keller, C., Eden, O.B. & Greaves, M.F. (1997) Backtracking leukemia to birth: Identification of clonotypic gene fusion sequences in neonatal bloodspots. Proc. natl Acad. Sci. USA, 94, 13950-13954
15. Gazzard, B. & Moyle, G. (1998) 1998 Revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee. Lancet, 352, 314-316
16. Gill-Super, H.J., Rothberg, P.G., Kobayashi, H., Freeman, A.I., Diaz, M.O. & Rowley, J.D. (1994) Clonal, nonconstitutional rearrangements of the MLL gene in infant twins with acute lymphoblastic leukemia: in utero chromosome rearrangement of 11q23. Blood, 83, 641-644
17. Graham, N.M., Hoover, D.R., Park, L.P., Stein, D.S., Phair, J.P., Mellors, J.W., Detels, R. & Saah, A.J. (1996) Survival in HIV-infected patients who have received zidovudine: Comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Multicenter AIDS Cohort Study Group. Ann. intern. Med., 124, 1031-1038
18. Hammer, S.M. (1996) Advances in antiretroviral therapy and viral load monitoring. AIDS, Suppl. 3, S1-S11
19. Hammer, S.M., Squires, K.E., Hughes, M.D., Grimes, J.M., Demeter, L.M., Currier, J.S., Eron, J.J., Jr, Feinberg, J.E., Balfour, H.H., Jr, Deyton, L.R., Chodakewitz, J.A. & Fischl, M.A. (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. New Engl. J. Med., 337, 725-733
20. Havlir, D.V., Marschner, I.C., Hirsch, M.S., Collier, A.C., Tebas, P., Bassett, R.L., Ioannidis, J.P., Holohan, M.K., Leavitt, R., Boone, G. & Richman, D.D. (1998) Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. New Engl. J. Med., 339, 1261-1268
21. IARC (1996) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 67, Human Immunodeficiency Viruses and Human T-cell Lymphotropic Viruses, Lyon, IARC Press
22. IARC (1997) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 70, Epstein-Barr Virus and Kaposi's Sarcoma Herpesvirus/Human Herpesvirus 8, Lyon, IARC Press
23. Isaacs, R.J., Davies, S.L., Sandri, M.I., Redwood, C., Wells, N.J. & Hickson, I.D. (1998) Physiological regulation of eukaryotic topoisomerase II. Biochim. biophys. Acta, 1400, 121-138
24. Larson, R.A., LeBeau, M.M., Vardiman, J.W. & Rowley, J.D. (1996) Myeloid leukemia after hematotoxins. Environ. Health Perspectives, 104, 1303-1307
25. Levine, C., Hiasa, H. & Marians, K.J. (1998) DNA gyrase and topoisomerase IV: Biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim. biophys. Acta, 1400, 29-43
26. McGregor, D.B., Rice, J.M. & Venitt, S., eds (1999) The Use of Short-and Medium-term Tests for Carcinogens and Data on Genetic Effects in Carcinogenic Hazard Evaluation (IARC Scientific Publications No. 146), Lyon, IARC Press
27. Megonigal, M.D., Rappaport, E.F., Jones, D.H., Williams, T.M., Lovett, B.D., Kelly, K.M., Lerou, P.H., Moulton, T., Budarf, M.L. & Felix, C.A. (1998) t(11;22)(q23;q11.2) in acute myeloid leukemia of infant twins fuses MLL with hCDCrel, a cell division cycle gene in the genomic region of deletion in DiGeorge and velocardiofacial syndromes. Proc. natl Acad. Sci. USA, 95, 6413-6418
28. Mofenson, L.M. (1998) Antiretroviral therapy and interruption of HIV perinatal transmission. Immunol. Allergy Clin. N. Am., 18, 441-463
29. Nitiss, J.L. (1998) Investigating the biological functions of DNA topoisomerases in eukaryote cells. Biochim. biophys. Acta, 1400, 63-82
30. Phillips, A.N., Katlama, C., Barton, S., Vella, S., Blaxhult, A., Clotet, B., Goebel, F.D., Hirschel, B., Pedersen, C. & Lundgren, J.D. (1998) Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group. J. acquir. Immune Defic. Syndrome hum. Retrovirol., 17, 239-244
31. Pialoux, G., Raffi, F., Brun-Vezinet, F., Meiffredy, V., Flandre, P., Gastaut, J.A., Dellamonica, P., Yeni, P., Delfraissy, J.F. & Aboulker, J.P. (1998) A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. New Engl. J. Med., 339, 1269-1276
32. Pommier, Y., Minford, J.K., Schwartz, R.E., Zwelling, L.A. & Kohn, K.W. (1985) Effects of the DNA intercalators 4′-(9-acridinylamino)methanesulfon-m-anisidide and 2-methyl-9-hydroxyellipticinium on topoisomerase II mediated DNA strand cleavage and strand passage. Biochemistry, 24, 6410-6416
33. Rabkin, C.S., Testa, M.A., Huang, J. & Von Roenn, J.H. (1999) Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in AIDS clinical trial group study participants. J. acquir. Immune Defic. Syndrome, 21 (Suppl. 1), S31-S33
34. Woynarowski, J.M., McCarthy, K., Reynolds, B., Beerman, T.A. & Denny, W.A. (1994) Topoisomerase II mediated DNA lesions induced by acridine-4-carboxamide and 2-(4-pyridyl)quinoline-8-carboxamide. Anticancer Drug Des., 9, 9-24